| Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results … C Orkin, E DeJesus, PE Sax, JR Arribas, SK Gupta, C Martorell, ... The Lancet HIV 7 (6), e389-e400, 2020 | 106 | 2020 |
| Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials KM Erlandson, CC Carter, K Melbourne, TT Brown, C Cohen, M Das, ... Clinical Infectious Diseases 73 (8), 1440-1451, 2021 | 99 | 2021 |
| Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials PE Sax, JR Arribas, C Orkin, A Lazzarin, A Pozniak, E DeJesus, ... EClinicalMedicine 59, 2023 | 39 | 2023 |
| Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study JJ Eron, SJ Little, G Crofoot, P Cook, PJ Ruane, D Jayaweera, ... The Lancet HIV 11 (3), e146-e155, 2024 | 22 | 2024 |
| Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants RK Acosta, GQ Chen, S Chang, R Martin, X Wang, H Huang, D Brainard, ... Journal of Antimicrobial Chemotherapy 76 (8), 2153-2157, 2021 | 14 | 2021 |
| The REDPINE Study: Efficacy and Safety of Remdesivir in People With Moderately and Severely Reduced Kidney Function Hospitalised for COVID-19 Pneumonia JR Santos, JD Goldman, KR Tuttle, JP Teixeira, Y Koullias, J Llewellyn, ... Poster paper presented at: 33rd European Congress of Clinical Microbiology …, 2023 | 6 | 2023 |
| Estimation of single-index models with fixed censored responses H Huang, Y Li, H Liang, Y Tang Statistica Sinica 30 (2), 829-843, 2020 | 6 | 2020 |
| Three-year outcomes of the fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir-containing regimens for initial treatment of HIV-1 … C Orkin, E DeJesus, PE Sax, JR Arribas, SK Gupta, C Martorell, ... Lancet HIV 3, e389-e400, 2020 | 5 | 2020 |
| Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy C Orkin, A Antinori, JK Rockstroh, S Moreno-Guillén, CT Martorell, ... AIDS 38 (7), 983-991, 2024 | 4 | 2024 |
| B/F/TAF FIVE-YEAR OUTCOMES in TREATMENT-NAÏVE ADULTS Wohl DA, Pozniak A, Workowski K, Hagins D, Daar ES, Orkin CL, Koenig E ... Topics in Antiviral Medicine 30 (1), 190, 2022 | 4* | 2022 |
| High‐dimensional single‐index models with censored responses H Huang, J Shangguan, X Li, H Liang Statistics in medicine 39 (21), 2743-2754, 2020 | 4 | 2020 |
| Decomposition feature selection with applications in detecting correlated biomarkers of bipolar disorders H Huang, Y Li, H Liang, CO Wu Statistics in medicine 38 (23), 4574-4582, 2019 | 4 | 2019 |
| Estimation in additive models with fixed censored responses H Huang, Y Tang, Y Li, H Liang Journal of Nonparametric Statistics 31 (1), 131-143, 2019 | 4 | 2019 |
| Four-year outcomes of B/F/TAF in treatment-naïve adults K Workowski, C Orkin, P Sax, D Hagins, E Koenig, J Stephens, A Wohl, ... Poster paper presented at: Conference on Retroviruses and Opportunistic …, 2021 | 3 | 2021 |
| 548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19 A Castagna, DSC Hui, KM Mullane, KM Mullane, M Jain, M Galli, ... Open Forum Infectious Diseases 7 (Supplement_1), S340-S340, 2020 | 3 | 2020 |
| Bi-level variable selection in high dimensional tobit models H Huang, J Shangguan, Y Li, H Liang Statistics and Its Interface 13 (2), 151-156, 2020 | 3 | 2020 |
| Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults C Orkin, PE Sax, J Arribas, S Gupta, C Martorell, JL Stephens, ... HIV MEDICINE 20, 94-95, 2019 | 3 | 2019 |
| Bi-level feature selection in high dimensional AFT models with applications to a genomic study H Huang, J Shangguan, P Ruan, H Liang Statistical applications in genetics and molecular biology 18 (5), 2019 | 3 | 2019 |
| 144-Week efficacy and safety of b/f/taf in treatment-naive adults age≥ 50 years A Mills, SK Gupta, C Brinson, K Workowski, A Clarke, A Antinori, ... Abstract, 2024 | 2 | 2024 |
| 1561. Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal … K Andreatta, PE Sax, DA Wohl, ML D’Antoni, H Huang, J Hindman, ... Open Forum Infectious Diseases 10 (Suppl 2), ofad500. 1396, 2023 | 2 | 2023 |
